Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Wound Healing of Split Thickness Skin Graft Donor Sites

Trial Profile

Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Wound Healing of Split Thickness Skin Graft Donor Sites

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2015

At a glance

  • Drugs Oleogel S10 (Primary)
  • Indications Wounds
  • Focus Registrational; Therapeutic Use
  • Sponsors Birken AG
  • Most Recent Events

    • 01 Apr 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 15 Nov 2014 Planned number of patients changed from 105 to 130, according to European Clinical Trials Database record.
    • 12 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top